As per reports, Johnson & Johnson’s (JNJ) Covid-19 vaccine is under review by the European Union’s drug regulator after four critical cases of unusual clots accompanied by low blood platelets were reported after taking the immunization with the J&J shot. The regulator is now investigating potential safety issues for two Covid vaccines after AstraZeneca Plc’s shot linked to a rare blood-clotting disorder.
The U.S. Food and Drug Administration informed that it has provided information to the EU regulator about reports of clots in a few individuals who were vaccinated with the J&J Covid-19 vaccine shot.
Though J&J’s vaccine is approved in the EU, its rollout in the bloc is not expected to start until later this month.
Peter Arlett, EMA’s head of analytics informed that the numbers of clot cases in people who took the J&J shot have been less so far in comparison to the total number of people getting the vaccine worldwide. “I think it would be fair to say there is intensive monitoring of this issue across the vaccines,” Arlett added.
Dow 30 component Johnson & Johnson (JNJ) is a worldwide healthcare-focused company that embraces research and science so that it can provide customers with innovative ideas, products, and services. To learn more about Johnson & Johnson (JNJ) and to continue to track its progress visit the Vista Partners Johnson & Johnson Coverage Page.
Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
Stay Informed! Stay Competitive! Please join us at Vista Partners and receive our FREE email updates throughout the week and view our exclusive content and research.